Shares of Balaji Amines Ltd. experienced a significant surge of up to 13% on Thursday, January 8, bucking the broader trend of a midcap sell-off. The rally was triggered by the company's announcement that it has received an eligibility certificate from the Directorate of Industries, Government of Maharashtra, for substantial government incentives related to its unit expansion. This development provides a major financial boost to the specialty chemicals manufacturer's growth plans.
The approval falls under the 'Mega Projects Investment Based 100% Gross Basis' category of the Maharashtra government's Package Scheme of Incentives 2013. According to a regulatory filing, this makes Balaji Amines eligible for an industrial promotion subsidy amounting to ₹258 crore. This subsidy is directly linked to 50% of the State Goods and Services Tax (SGST) payable on the sale of eligible finished products manufactured within Maharashtra.
In addition to the direct subsidy, the incentive package includes a complete exemption from electricity duty and a 100% waiver on stamp duty payments. These benefits are set to provide considerable operational cost savings for the company over the next several years. The eligibility period for these incentives is for seven years, commencing on January 1, 2024, and concluding on December 31, 2030.
The market responded positively to the news, with Balaji Amines' stock price climbing sharply. The share price rose by 9.73% to reach ₹1,177 and ultimately closed at ₹1,194.90, an 11.63% increase from its previous close of ₹1,070.50. This jump is particularly noteworthy as it occurred amidst a challenging market for midcap stocks. However, despite this single-day gain, the stock's longer-term performance shows it is still down approximately 38.5% over the past six months, indicating a potential reversal of its recent downward trend.
Balaji Amines has demonstrated a strong financial position, which supports its expansion ambitions. For the first half of the fiscal year 2026 (H1FY26), the company reported a consolidated revenue of ₹715 crore and an EBITDA of ₹131 crore, resulting in an EBITDA margin of 18%. The Profit After Tax (PAT) for the same period stood at ₹74 crore, with a PAT margin of 10%. The company's management has expressed confidence in a gradual improvement in operating performance as new capacities become operational.
The company is actively pursuing several expansion projects, all of which are being funded through internal accruals, highlighting its robust balance sheet and prudent financial management. Key projects include the DME plant at Unit 4 and the N-Methyl Morpholine projects, both expected to be commissioned during FY2025-26. Furthermore, an acetonitrile expansion based on an improved process is on track for commissioning in FY2026-27.
Balaji Specialty Chemicals Limited, a subsidiary of the company, is also making significant progress on its ₹750 crore expansion plan. This project has also been granted 'mega project' status under the Maharashtra government's Package Scheme of Incentives 2019. The expansion covers a diverse range of specialty products, including hydrogen cyanide, sodium cyanide, and EDTA. The Unit 1 brownfield expansion for EDA-based products is slated for commissioning by September 2026, while the Unit 2 greenfield project is expected to be commissioned by December 2026.
The approval for the ₹258 crore incentive package is a significant positive catalyst for Balaji Amines. It not only reduces the financial burden of its ambitious expansion plans but also enhances its profitability and cash flow over the next seven years. By leveraging internal accruals for funding, the company maintains a strong, debt-free balance sheet, which is a key advantage in a capital-intensive industry. This government support, combined with a clear roadmap for capacity expansion, positions Balaji Amines to capitalize on growing demand in the specialty chemicals sector and potentially deliver improved shareholder value in the coming years.
Hey, I’m Aaditya, founder of Multibagg AI. If you enjoyed reading this, you’ve only seen a small part of what’s possible.
With Multibagg AI, you don’t just read. You ask questions directly to Iris and get clarity, not noise. You discover new ideas and companies before they become obvious. You connect your portfolio and let AI help you truly understand what you own. And you track day-to-day corporate updates of the businesses that matter to you, all in one place.
It’s all about thinking better as an investor. Welcome to a smarter way of doing stock market research.